Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Breaking Down TeraWulf: 5 Analysts Share Their Views (Benzinga) +++ TERAWULF Aktie +4,15%

News zum Sektor Gesundheit aus Australien & Ozeanien

Zum Sektor Gesundheit gehören Unternehmen der Pharmaka- & Biotechnologiebranche, Produzenten von medizintechnischen Geräten, Gesundheitsdienste, Kliniken und Pflegeeinrichtungen.
 >Gesundheit ETFs & Fonds 
Es sind 102 ETFs & Fonds zum Sektor Gesundheit bekannt.
 >Aktien zum Sektor Gesundheit 
Es sind 1553 Aktien zum Sektor Gesundheit bekannt.
 
27.02.26 - 18:36
Health Care Roundup: Market Talk (WSJ EN)
 
Find insight on Sandoz, Ramsay Health Care and more in the latest Market Talks covering Health Care....
27.02.26 - 13:03
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging (GlobeNewswire EN)
 
MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence (AI)....
27.02.26 - 09:33
Mesoblast misses H1 estimates (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.02.26 - 04:48
Why 4DMedical, Block, PEXA, and Weebit Nano shares are launching higher today (Fool)
 
These shares are ending the week with a bang. But why? The post Why 4DMedical, Block, PEXA, and Weebit Nano shares are launching higher today appeared first on The Motley Fool Australia....
27.02.26 - 03:48
Neuren shares dip after FY25 result. Here′s what stood out (Fool)
 
Royalties rise at Neuren, but total income falls for FY25. The post Neuren shares dip after FY25 result. Here's what stood out appeared first on The Motley Fool Australia....
27.02.26 - 01:48
What′s going on with Mesoblast shares today? (Fool)
 
This biotech was up almost 9% before sinking into the red. The post What's going on with Mesoblast shares today? appeared first on The Motley Fool Australia....
27.02.26 - 01:18
Earnings Call: SomnoMed mit starkem Wachstum im ersten Halbjahr GJ26 (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
27.02.26 - 00:36
Neuren Pharmaceuticals earnings: Profits up, pipeline builds in 2025 (Fool)
 
Neuren saw 2025 DAYBUE royalties jump 15% to $65 million, with profit after tax reaching $30 million and a new buy-back announced. The post Neuren Pharmaceuticals earnings: Profits up, pipeline builds in 2025 appeared first on The Motley Fool Australia....
27.02.26 - 00:24
Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026 (Fool)
 
Mesoblast posts strong H1 FY2026 results on the back of Ryoncil®'s US launch and robust revenue growth. The post Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026 appeared first on The Motley Fool Australia....
26.02.26 - 22:36
Summerset Group reports record FY25 profit and strong sales (Fool)
 
Summerset Group delivered record underlying profit and strong sales in FY25, boosting confidence for the year ahead. The post Summerset Group reports record FY25 profit and strong sales appeared first on The Motley Fool Australia....
26.02.26 - 21:36
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial (PR Newswire)
 
Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3......
26.02.26 - 21:24
Buy, hold, sell: Breville, CSL, and EOS shares (Fool)
 
Are these popular shares worth adding to your portfolio? Here's what one leading broker thinks. The post Buy, hold, sell: Breville, CSL, and EOS shares appeared first on The Motley Fool Australia....
26.02.26 - 18:12
Clinuvel Pharmaceuticals reports 2H results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.02.26 - 15:18
Gamechanger MDMA? Bioxyne Limited verbucht Umsatzrekord mit innovativen Arzneimitteln (IRW Press)
 
Während der globale Markt für die Behandlung von posttraumatischen Belastungsstörungen (PTBS) auf über 2,5 Milliarden USD zusteuert, setzt Bioxyne Limited neue Maßstäbe. Als Pionier lieferte das......
26.02.26 - 12:24
Clinuvel meldet Rekordumsatz, doch Kostenanstieg belastet Aktie (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
26.02.26 - 11:49
1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth (Fool)
 
Telix Pharmaceuticals focuses on radiopharmaceuticals for the diagnosis and treatment of cancer....
26.02.26 - 10:24
Ramsay Health Care Swings To Profit After Tax In H1, Stock Up (AFX)
 
CANBERA (dpa-AFX) - Ramsay Health Care Ltd (RHC.AX,RMYHY), a healthcare services provider, reported profit before income tax for the first-half, compared to loss last year. The earnings were backe......
26.02.26 - 04:00
Why Ramsay Health Care shares are storming 10% higher (Fool)
 
Investors applaud strong improved first-half FY26 results. The post Why Ramsay Health Care shares are storming 10% higher appeared first on The Motley Fool Australia....
26.02.26 - 03:48
Why Neuren shares are jumping more than 6% today (Fool)
 
Neuren shares jump after an updated DAYBUE sales outlook. The post Why Neuren shares are jumping more than 6% today appeared first on The Motley Fool Australia....
26.02.26 - 02:48
Bioxyne Boosts FY26 Outlook on Strong Performance and International Growth (Small Caps)
 
Bioxyne lifts FY26 EBITDA guidance to AUD16.5-19m after record H1 FY2026 with AUD31.3m revenue (+149% YoY); expands capacity, enters UK/Germany/LATAM....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Froher Mut braucht keinen Doktor. - Sprichwort Deutschland
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!